Point72 DIFC Ltd Buys Shares of 17,100 ICU Medical, Inc. (NASDAQ:ICUI)

Point72 DIFC Ltd purchased a new stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 17,100 shares of the medical instruments supplier’s stock, valued at approximately $3,116,000.

Other institutional investors have also added to or reduced their stakes in the company. Dimensional Fund Advisors LP raised its position in ICU Medical by 21.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 311,542 shares of the medical instruments supplier’s stock worth $36,996,000 after buying an additional 55,588 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in ICU Medical by 10.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 301,107 shares of the medical instruments supplier’s stock worth $54,868,000 after acquiring an additional 27,927 shares during the period. WCM Investment Management LLC raised its holdings in shares of ICU Medical by 1.3% during the third quarter. WCM Investment Management LLC now owns 259,481 shares of the medical instruments supplier’s stock valued at $45,272,000 after acquiring an additional 3,407 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in ICU Medical by 11.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 216,509 shares of the medical instruments supplier’s stock worth $25,710,000 after purchasing an additional 22,310 shares during the last quarter. Finally, Federated Hermes Inc. grew its stake in ICU Medical by 9.3% during the 2nd quarter. Federated Hermes Inc. now owns 215,808 shares of the medical instruments supplier’s stock valued at $25,627,000 after acquiring an additional 18,301 shares in the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

Insider Activity

In other news, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $178.46, for a total transaction of $2,141,520.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at approximately $18,665,666.78. The trade was a 10.29 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director David C. Greenberg sold 972 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $158.11, for a total value of $153,682.92. Following the sale, the director now directly owns 5,037 shares in the company, valued at approximately $796,400.07. The trade was a 16.18 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 40,364 shares of company stock worth $6,869,878. 6.70% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

ICUI has been the subject of several analyst reports. StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th. Jefferies Financial Group assumed coverage on shares of ICU Medical in a report on Monday, October 14th. They issued a “hold” rating and a $183.00 price objective on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. KeyCorp increased their price target on shares of ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, November 13th. Finally, Raymond James boosted their target price on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, ICU Medical has a consensus rating of “Moderate Buy” and a consensus target price of $173.00.

ICU Medical Stock Down 2.7 %

Shares of NASDAQ:ICUI opened at $156.64 on Wednesday. The firm has a market cap of $3.83 billion, a PE ratio of -34.28 and a beta of 0.62. The company has a fifty day simple moving average of $173.90 and a 200 day simple moving average of $148.43. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. ICU Medical, Inc. has a 12-month low of $83.26 and a 12-month high of $196.26.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.